| TRIDENT LIFELINE Back to ShareHolding Pattern | 
Last 5 Year Total Public Shareholding ShareHolding (%) History of TRIDENT LIFELINE
Last 8 Quarters| Sep2025 | Jun2025 | Mar2025 | Dec2024 | Sep2024 | Jun2024 | Mar2024 | Dec2023 | ||
|---|---|---|---|---|---|---|---|---|---|
| 36.89 % | 36.96 % | 36.96 % | 37.01 % | 37.01 % | 34.49 % | 32.52 % | 29.96 % | ||
What is the latest Total Public Shareholding Shareholding of TRIDENT LIFELINE ?
| Year | Total Public Shareholding | 
|---|---|
| Sep2025 | 36.89 % | 
| Jun2025 | 36.96 % | 
| Mar2025 | 36.96 % | 
| Dec2024 | 37.01 % | 
| Sep2024 | 37.01 % | 
| Jun2024 | 34.49 % | 
| Mar2024 | 32.52 % | 
| Dec2023 | 29.96 % | 
How is Total Public Shareholding Shareholding of TRIDENT LIFELINE Trending?
| Years | Total Public Shareholding | % Change | |
|---|---|---|---|
| Sep2025 | 36.89 % | -0.19 | |
| Jun2025 | 36.96 % | 0.00 | |
| Mar2025 | 36.96 % | -0.14 | |
| Dec2024 | 37.01 % | 0.00 | |
| Sep2024 | 37.01 % | 7.31 | |
| Jun2024 | 34.49 % | 6.06 | |
| Mar2024 | 32.52 % | 8.54 | |
| Dec2023 | 29.96 % | - | |
Compare Total Public Shareholding ShareHolding of peers of TRIDENT LIFELINE
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| TRIDENT LIFELINE | ₹363.0 Cr | 4.3% | 6.8% | -0.4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹408,751.0 Cr | 0.2% | 7.1% | -7.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹176,634.0 Cr | 1% | 16.8% | 12.7% | Stock Analytics | |
| CIPLA | ₹124,437.0 Cr | -2.7% | 3.5% | 6.2% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹121,871.0 Cr | 0.6% | 0.4% | 4.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹100,333.0 Cr | -6.4% | -2.7% | -3.9% | Stock Analytics | |
TRIDENT LIFELINE Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year | 
| TRIDENT LIFELINE | 4.3% | 6.8% | -0.4% | 
| SENSEX | -0.2% | 5% | 5.4% | 
You may also like the below Video Courses
 
                     
                                     
                                     
                                    